AstraZeneca reports Phase 3 win for hypoparathyroidism drug eneboparatidenews2025-03-17T16:50:50+00:00March 17th, 2025|Endpoints News|
All selected drugmakers agree to round 2 of price negotiationsnews2025-03-17T16:16:44+00:00March 17th, 2025|Endpoints News|
Kennedy’s anti-vaccine actions shouldn’t surprise anyonenews2025-03-17T14:02:44+00:00March 17th, 2025|Endpoints News|
Otsuka’s Taiho buys Swiss startup Araris with three ADCs nearing the clinicnews2025-03-17T11:30:33+00:00March 17th, 2025|Endpoints News|
Avidity heads to FDA with exon 44 skipping Duchenne muscular dystrophy drugnews2025-03-17T11:00:15+00:00March 17th, 2025|Endpoints News|
Dr. Oz says he would defend Medicare drug price negotiationsnews2025-03-14T19:07:18+00:00March 14th, 2025|Endpoints News|
Federal Circuit ruling keeps Amgen’s Eylea biosimilar on the marketnews2025-03-14T19:05:53+00:00March 14th, 2025|Endpoints News|
UK’s drugmaker rebate plan draws scrutiny from industrynews2025-03-14T17:47:32+00:00March 14th, 2025|Endpoints News|
Recipharm hits record revenue, eyes GLP-1 deals for growth news2025-03-14T17:07:23+00:00March 14th, 2025|Endpoints News|
RFK Jr. convened roundtable around ways to reduce stem cell regulationnews2025-03-14T15:36:02+00:00March 14th, 2025|Endpoints News|
